Trial Profile
A Phase II Trial to Evaluate Crizotinib in the Neoadjuvant Setting in Patients With Surgically Resectable, ALK, ROS1, or MET-oncogene Positive Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2022
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Apr 2021 Status changed from active, no longer recruiting to completed.
- 21 Dec 2020 Planned End Date changed from 1 Oct 2021 to 31 Jan 2022.
- 15 Dec 2020 Planned primary completion date changed from 1 Aug 2021 to 31 Jan 2022.